HK1123188A1 - Liquid formulations - Google Patents

Liquid formulations

Info

Publication number: HK1123188A1
Authority: HK; Hong Kong
Prior art keywords: liquid formulations; formulations; liquid
Prior art date: 2005-08-09

Application number

HK09100446.1A

Other languages

English (en)

Inventor

Vivian Georgousis

Wei-Qin Tong

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-09

Filing date

2009-01-16

Publication date

2009-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1123188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-16 Application filed by Novartis Ag filed Critical Novartis Ag

2009-06-12 Publication of HK1123188A1 publication Critical patent/HK1123188A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

HK09100446.1A 2005-08-09 2009-01-16 Liquid formulations HK1123188A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US70682005P	2005-08-09	2005-08-09
PCT/US2006/030836 WO2007021666A2 (en)	2005-08-09	2006-08-08	Liquid formulations

Publications (1)

Publication Number	Publication Date
HK1123188A1 true HK1123188A1 (en)	2009-06-12

Family

ID=37734410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK09100446.1A HK1123188A1 (en)	2005-08-09	2009-01-16	Liquid formulations

Country Status (24)

Country	Link
US (4)	US20080194526A1 (ru)
EP (1)	EP1915130B1 (ru)
JP (1)	JP5068755B2 (ru)
KR (1)	KR101473494B1 (ru)
CN (1)	CN101237852B (ru)
AR (1)	AR056020A1 (ru)
AU (1)	AU2006280138B2 (ru)
BR (1)	BRPI0615009A2 (ru)
CA (1)	CA2618018C (ru)
EC (1)	ECSP088165A (ru)
GT (1)	GT200600350A (ru)
HK (1)	HK1123188A1 (ru)
IL (1)	IL188915A0 (ru)
MA (1)	MA29736B1 (ru)
MX (1)	MX2008001967A (ru)
MY (1)	MY145111A (ru)
NO (1)	NO20081218L (ru)
NZ (2)	NZ593121A (ru)
PE (2)	PE20070337A1 (ru)
RU (2)	RU2470631C2 (ru)
TN (1)	TNSN08061A1 (ru)
TW (1)	TWI317289B (ru)
WO (1)	WO2007021666A2 (ru)
ZA (1)	ZA200800640B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2359821A1 (en) *	2004-11-29	2011-08-24	Novartis AG	Dosage regimen of an s1p receptor agonist
KR101434522B1 (ko)	2005-11-09	2014-08-26	오닉스 세라퓨틱스, 인크.	효소 저해를 위한 화합물
CA2657213C (en)	2006-06-19	2017-01-03	Proteolix, Inc.	Peptide epoxyketones for proteasome inhibition
EP2207791B2 (en)	2007-10-04	2019-08-07	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
DK2952177T3 (da) *	2007-10-12	2021-04-26	Novartis Ag	Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
WO2009155475A1 (en) *	2008-06-20	2009-12-23	Novartis Ag	Paediatric compositions for treating1 multiple sclerosis
US20110236428A1 (en)	2008-10-21	2011-09-29	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
MX2011004924A (es)	2008-11-11	2011-05-30	Novartis Ag	Sales de fingolimod.
CN104803902A (zh) *	2008-12-18	2015-07-29	诺华股份有限公司	1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的半富马酸盐
BRPI0922457A2 (pt) *	2008-12-18	2015-12-15	Novartis Ag	forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
RU2011129229A (ru)	2008-12-18	2013-01-27	Новартис Аг	Новые соли
AU2010217605B2 (en) *	2009-02-24	2012-07-26	Novartis Ag	Ceramide-analogous metabolites
US20100243087A1 (en) *	2009-03-03	2010-09-30	Millipore Corporation	System and pump apparatus for processing fluid samples
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
EP2498793B1 (en)	2009-11-13	2019-07-10	Onyx Therapeutics, Inc.	Oprozomib for use in metastasis suppression
WO2011109355A1 (en)	2010-03-01	2011-09-09	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
EA026144B9 (ru)	2011-01-07	2021-10-26	Новартис Аг	Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
TW201414751A (zh)	2012-07-09	2014-04-16	歐尼克斯治療公司	肽環氧酮蛋白酶抑制劑之前驅藥物
RU2496486C1 (ru)	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6316422B2 (ja)	2013-07-29	2018-04-25	アイザントドラッグリサーチソリューションズプライベートリミテッドＡｉｚａｎｔＤｒｕｇＲｅｓｅａｒｃｈＳｏｌｕｔｉｏｎｓＰｖｔＬｔｄ	フィンゴリモドの医薬組成物
WO2016042493A1 (en)	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CA3074043A1 (en)	2017-09-27	2019-04-04	Novartis Ag	Parenteral formulation comprising siponimod
US20200306222A1 (en)	2017-09-29	2020-10-01	Novartis Ag	Dosing Regimen of Siponimod
EP3687530A1 (en)	2017-09-29	2020-08-05	Novartis AG	Dosing regimen of siponimod
WO2021214717A1 (en)	2020-04-23	2021-10-28	Novartis Ag	Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2579602B2 (ja) *	1992-10-21	1997-02-05	吉富製薬株式会社	２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
DE19645549A1 (de) *	1996-11-05	1998-05-07	Bayer Ag	Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan
EP1002792B1 (en) *	1997-04-04	2004-07-14	Mitsubishi Pharma Corporation	2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US6727283B2 (en) *	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
JP4627356B2 (ja) *	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
JPWO2003020313A1 (ja) *	2001-09-04	2004-12-16	小野薬品工業株式会社	スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
PT1431284E (pt) *	2001-09-27	2008-01-21	Kyorin Seiyaku Kk	Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
ATE412408T1 (de) *	2002-05-16	2008-11-15	Novartis Pharma Gmbh	Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
CA2539438A1 (en) *	2003-10-01	2005-04-14	Merck And Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists

2006
- 2006-08-04 GT GT200600350A patent/GT200600350A/es unknown
- 2006-08-07 PE PE2006000957A patent/PE20070337A1/es not_active Application Discontinuation
- 2006-08-07 PE PE2009001335A patent/PE20100149A1/es not_active Application Discontinuation
- 2006-08-07 AR ARP060103432A patent/AR056020A1/es unknown
- 2006-08-08 RU RU2011106364/15A patent/RU2470631C2/ru not_active IP Right Cessation
- 2006-08-08 BR BRPI0615009-8A patent/BRPI0615009A2/pt not_active IP Right Cessation
- 2006-08-08 TW TW095129275A patent/TWI317289B/zh not_active IP Right Cessation
- 2006-08-08 NZ NZ593121A patent/NZ593121A/xx not_active IP Right Cessation
- 2006-08-08 WO PCT/US2006/030836 patent/WO2007021666A2/en active Application Filing
- 2006-08-08 NZ NZ565696A patent/NZ565696A/en not_active IP Right Cessation
- 2006-08-08 EP EP06800936.4A patent/EP1915130B1/en active Active
- 2006-08-08 CN CN2006800286163A patent/CN101237852B/zh not_active Expired - Fee Related
- 2006-08-08 AU AU2006280138A patent/AU2006280138B2/en not_active Ceased
- 2006-08-08 JP JP2008526120A patent/JP5068755B2/ja not_active Expired - Fee Related
- 2006-08-08 CA CA2618018A patent/CA2618018C/en not_active Expired - Fee Related
- 2006-08-08 US US11/997,909 patent/US20080194526A1/en not_active Abandoned
- 2006-08-08 MY MYPI20063826A patent/MY145111A/en unknown
- 2006-08-08 MX MX2008001967A patent/MX2008001967A/es active IP Right Grant
- 2006-08-08 RU RU2008108887/15A patent/RU2428180C2/ru not_active IP Right Cessation
2008
- 2008-01-21 IL IL188915A patent/IL188915A0/en unknown
- 2008-01-22 ZA ZA200800640A patent/ZA200800640B/xx unknown
- 2008-02-05 KR KR1020087003142A patent/KR101473494B1/ko not_active IP Right Cessation
- 2008-02-08 MA MA30632A patent/MA29736B1/fr unknown
- 2008-02-08 EC EC2008008165A patent/ECSP088165A/es unknown
- 2008-02-08 TN TNP2008000061A patent/TNSN08061A1/en unknown
- 2008-03-07 NO NO20081218A patent/NO20081218L/no not_active Application Discontinuation
2009
- 2009-01-16 HK HK09100446.1A patent/HK1123188A1/xx not_active IP Right Cessation
2012
- 2012-09-07 US US13/606,118 patent/US20120328664A1/en not_active Abandoned
2013
- 2013-12-06 US US14/099,072 patent/US20150080347A9/en not_active Abandoned
2015
- 2015-10-15 US US14/883,729 patent/US20160030572A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2006280138B2 (en)	2010-03-04
KR101473494B1 (ko)	2014-12-16
RU2470631C2 (ru)	2012-12-27
KR20080035608A (ko)	2008-04-23
JP2009504653A (ja)	2009-02-05
US20120328664A1 (en)	2012-12-27
AU2006280138A1 (en)	2007-02-22
TWI317289B (en)	2009-11-21
PE20070337A1 (es)	2007-04-18
CN101237852A (zh)	2008-08-06
NO20081218L (no)	2008-04-29
PE20100149A1 (es)	2010-03-24
TNSN08061A1 (en)	2009-07-14
BRPI0615009A2 (pt)	2011-05-03
GT200600350A (es)	2007-03-28
JP5068755B2 (ja)	2012-11-07
TW200738277A (en)	2007-10-16
RU2008108887A (ru)	2009-09-20
CA2618018A1 (en)	2007-02-22
ECSP088165A (es)	2008-03-26
IL188915A0 (en)	2008-04-13
MA29736B1 (fr)	2008-09-01
US20160030572A1 (en)	2016-02-04
US20150080347A9 (en)	2015-03-19
WO2007021666A3 (en)	2007-05-31
EP1915130B1 (en)	2016-07-13
WO2007021666A2 (en)	2007-02-22
ZA200800640B (en)	2008-12-31
NZ593121A (en)	2012-09-28
RU2428180C2 (ru)	2011-09-10
CN101237852B (zh)	2011-01-26
US20080194526A1 (en)	2008-08-14
EP1915130A2 (en)	2008-04-30
MY145111A (en)	2011-12-30
NZ565696A (en)	2011-06-30
CA2618018C (en)	2016-05-31
RU2011106364A (ru)	2012-08-27
US20140179636A1 (en)	2014-06-26
MX2008001967A (es)	2008-03-26
AR056020A1 (es)	2007-09-12

Publication	Publication Date	Title
HK1123188A1 (en)	2009-06-12	Liquid formulations
GB2424581B (en)	2007-10-10	Formulations
PL1986606T3 (pl)	2019-08-30	Ciekłe formulacje zawierające fenylefrynę
IL189856A0 (en)	2008-12-29	New formulation
EP1909584A4 (en)	2010-07-07	PRENYLFLAVONOID FORMULATIONS
TWI370115B (en)	2012-08-11	New formulation
EP2046930A4 (en)	2012-06-27	FORMULATIONS BASED ON RHAMNOLIPIDS
IL185773A0 (en)	2008-01-06	Formulations
EP1951693A4 (en)	2012-05-30	SOLID FORMULATIONS
GB0526419D0 (en)	2006-02-08	Formulation
GB0517673D0 (en)	2005-10-05	Formulation
PL1928232T3 (pl)	2016-12-30	Stała formulacja
GB0520176D0 (en)	2005-11-09	Use
GB0511190D0 (en)	2005-07-06	Use
EP1951258A4 (en)	2013-01-02	LIQUID FORMULATIONS
GB0501030D0 (en)	2005-02-23	Formulation
GB0502250D0 (en)	2005-03-09	Use
GB0526031D0 (en)	2006-02-01	Use
GB0526032D0 (en)	2006-02-01	Use
GB0403769D0 (en)	2004-03-24	Liquid composition
GB0522917D0 (en)	2005-12-21	Formulations
GB0526322D0 (en)	2006-02-01	Formulations
GB0518878D0 (en)	2005-10-26	Formulations
GB0520388D0 (en)	2005-11-16	Formulations
GB0507811D0 (en)	2005-05-25	Formulation

Legal Events

Date	Code	Title	Description
2016-03-04	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20150808